课题基金 / 基金详情

Assay Development

Assay Development
检测开发
批准号:
8379686
负责人:
Eduard A. Sergienko
金额:
$262.56万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
已结题
起止时间:
至 2014-05-31

项目摘要

项目成果

Eduard A. Sergienko的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
UNIT 1. ASSAY DEVELOPMENT, ADAPTATION, AND IMPLEMENTATION Unit 1 is a responsible for all assay activities, as well as for post-HTS hit characterization, performing: (a) assay development and adaptation for HTS and HCS, (b) initial characterization of hits through confirmatory assays and ECso/ICsq determination, (c) secondary and orthogonal assays and screens, (d) testing of analogs and chemistry-optimized compounds, and (e) preliminary mode-of-action studies on hits and optimized compounds. Unit 1 surpassed the MLSCN goals with the development and adaptation of 36 primary HTS assays consisting of a variety of read-outs, resulting in 39 screening campaigns thus far. The Unit also developed 27 secondary/counter assays to support the MLSCN projects. Additionally, the Unit supported 22 hit optimization/SAR projects using 41 dose-response assays, generated >24,000 IC50 10-point curves in duplicate and performed >20 mode-of-action studies. Unit 1 is organized into two subunits: subunit 1A will develop and implement all HTS assays, while subunit 1B is responsible for developing and optimizing software algorithms for HCS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer
Assay Development
Assay Development
海外基金